Trials / Withdrawn
WithdrawnNCT05645887
Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure.
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Albimmune SL · Industry
- Sex
- All
- Age
- 18 Years – 84 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this phase 2, multicenter, randomized, controlled study is to evaluate the effect of albumin treatment on B cell and other immune cell gene exptression in adults with septic shock.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Human albumin | Human albumin from day 0 to 7 if serum albumin concentrations \<35g/l. |
| OTHER | Saline solution | Saline solution from day 0 to day 7. |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2024-05-23
- Completion
- 2024-05-23
- First posted
- 2022-12-12
- Last updated
- 2024-07-31
Source: ClinicalTrials.gov record NCT05645887. Inclusion in this directory is not an endorsement.